Great — here’s a focused, citation-backed company reference + market snapshot for the Ankylosing Spondylitis (AS) — drugs market, organised to your headings and including the company/product values I could confirm from public sources.

This versatile research report is presenting crucial details on market relevant information, harping on ample minute details encompassing a multi-dimensional market that collectively maneuver growth in the global Ankylosing Spondylitis Drugs market.

This holistic report presented by the report is also determined to cater to all the market specific information and a take on business analysis and key growth steering best industry practices that optimize million-dollar opportunities amidst staggering competition in Ankylosing Spondylitis Drugs market.

Note on scope: “AS drugs market” here covers prescription treatments used for ankylosing spondylitis / axial spondyloarthritis (biologics — TNF and IL-17 inhibitors — plus JAK inhibitors and other Rx therapies). Where companies don’t report “AS-only” revenue, I show the product or product-line sales (the usual industry practice).

Read complete report at: https://www.thebrainyinsights.com/report/ankylosing-spondylitis-drugs-market-12527

Market snapshot (representative estimates)

• Global market size (2024): ~USD 6.3 billion (Grand View Research estimate for the ankylosing spondylitis market in 2024; multiple market reports place the near-term market in the mid-single-digit billions and forecast mid-single to high-single digit CAGRs). 

Recent developments

• Shift in standard of care / treatment mix: IL-17 inhibitors (e.g., secukinumab/Cosentyx and ixekizumab/Taltz) are now established first-line biologic options after TNF inhibitors for many patients; JAK inhibitors (e.g., upadacitinib/Rinvoq) have received regulatory approvals for active AS/nr-axSpA and are being rolled out commercially. 

• Blockbuster immunology drugs driving share: Cosentyx and Taltz have grown rapidly and contribute material immunology revenues — they are becoming dominant brand drivers across related SpA/psoriatic/autoimmune indications.

Drivers

• Rising diagnosis and specialist referral rates (greater awareness among rheumatologists and primary care).

• Proven efficacy of biologics (TNF, IL-17) and new oral JAK options expanding treatment choices and patient uptake.

• Payer-accepted long-term benefit (reduced disability, improved productivity) that supports premium pricing for effective biologics.

Restraints

• High drug/therapy cost and payer access constraints in some countries (limits uptake in lower-resource settings).

• Safety/regulatory scrutiny for JAK inhibitors across indications (regulators and payers watch safety signals closely).

• Biosimilars / price competition for older TNF agents pressuring unit economics in some markets.

Regional segmentation analysis

• North America: high per-patient spend, early adoption of new mechanisms (IL-17, JAK). Large commercial & specialty clinic base. 

• Europe: strong biologic uptake but price regulation and biosimilar competition shape product mix. 

• Asia-Pacific / Latin America / MENA: increasing diagnosis and treatment rates drive fastest volume growth, but access/payer mix varies by country.

Emerging trends

• Market share growth for IL-17 inhibitors in axial spondyloarthritis subgroups. 

• Oral JAK inhibitors (Rinvoq/upadacitinib and others) becoming important treatment options after TNF failure and in some first-line settings (depending on label/payer). 

• Biosimilars & pricing pressure for first-generation TNF agents; branded differentiation (convenience, outcomes data) matters more.

Top use cases

• Active ankylosing spondylitis (reduce inflammation, control pain, slow functional decline).

• Non-radiographic axial spondyloarthritis (nr-axSpA) — several drugs now approved for both AS and nr-axSpA, expanding the treated population.

Major challenges

• Payer negotiations (high list prices vs outcomes & budget impact).

• Long-term safety data & label changes for newer oral agents (JAK class).

• Converting diagnosed but untreated patients into long-term treated cohorts (adherence, monitoring).

Attractive opportunities

• Positioning oral JAKs (where safe and reimbursed) for patients who prefer oral therapy or have failed biologics.

• Value-based contracting for high-cost biologics/JAKs (outcome guarantees, risk-sharing).

• Real-world evidence & biomarker work to segment responders and improve cost-effectiveness. 

Key factors of market expansion

1. Speed of guideline updates and physician uptake for IL-17 and JAK classes. 

2. Payer willingness to fund new oral options and high-cost biologics.

3. Biosimilar penetration and its effect on therapy sequencing and total spend.

Top companies — product references & confirmed values

Important: most companies don’t publish “AS-only” revenues. below are product-level or product-line values (best publicly available figures) — useful to size who captures value in the AS drugs market.

1. Novartis — Cosentyx (secukinumab)

   • 2024 net product sales: USD 6,141 million (Cosentyx). Cosentyx is a leading IL-17A inhibitor with broad SpA/psoriasis/psoriatic arthritis usage and is a principal revenue driver for Novartis’ immunology franchise.

2. Eli Lilly — Taltz (ixekizumab)

   • 2024 global revenue (Taltz): ~USD 3.2 billion (2024 reporting / market summaries). Taltz is another IL-17 inhibitor used in AS/psoriatic disease and has shown strong growth.

   • AbbVie — Rinvoq (upadacitinib) and legacy TNF exposure (Humira)

3. • Rinvoq 2024 revenue: reported ~USD 5.97 billion (2024 sales figure cited in coverage of AbbVie results & exclusivity commentary). Rinvoq is an oral JAK inhibitor approved for AS and other immune diseases and is a material commercial asset. (AbbVie also still earns from TNF class historically via Humira and from other immunology brands.) 

4. UCB — Cimzia (certolizumab pegol)

   • Cimzia (certolizumab) reported strong sales contribution; UCB reported net sales €5.61–6.15B (2024 company reporting) with Cimzia a core immunology product (Cimzia net sales run into high-hundreds of millions to low billions depending on reporting period). Cimzia is widely used in TNF-mediated diseases and contributes materially to UCB’s immunology portfolio.

5. Johnson & Johnson (Janssen) — Simponi (golimumab)

   • Golimumab / Simponi is a major TNF-alpha product (market reports estimate the golimumab/Simponi market in the low-billion USD range in 2024). Janssen/Johnson & Johnson remains a key supplier of TNF agents used in AS.

Sources (selected — most load-bearing)

• Grand View Research — Ankylosing Spondylitis market size & forecast (2024 estimate ~USD 6.29B). 

• Novartis product sales (Cosentyx net sales USD 6,141M in 2024).

• Eli Lilly / market reporting on Taltz (ixekizumab) 2024 sales ~USD 3.2B. 

• Reuters / coverage of AbbVie/Rinvoq and exclusivity / sales commentary (Rinvoq ≈ USD 5.97B in 2024).

• Spondylitis Association / clinical info on drug classes approved for AS (TNF, IL-17, JAK approvals & indications). 

(Additional market and product references used above are listed inline in each section.)

If you want this packaged as a spreadsheet (top 12 companies + product names + latest available product revenues and source links) or a 6-slide summarised deck, I can generate that right away — tell me which format you prefer and I’ll build it.